Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
5
63%
Ph not_applicable
1
13%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 4Post-market surveillance
5(71.4%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(2)
Other(6)

Detailed Status

unknown6
Completed2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 45 (71.4%)
N/A1 (14.3%)

Trials by Status

completed225%
unknown675%

Recent Activity

0 active trials
Showing 5 of 8
completednot_applicable

Clinical Study of Bowel Preparation Before Colonoscopy

NCT06091735
unknown

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

NCT04943679
unknownphase_4

The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg

NCT03801538
unknownphase_4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02838810
unknownphase_4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02745704
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06091735Not Applicable

Clinical Study of Bowel Preparation Before Colonoscopy

Completed
NCT04943679

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Unknown
NCT03801538Phase 4

The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg

Unknown
NCT02838810Phase 4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Unknown
NCT02745704Phase 4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Unknown
NCT02908763Phase 4

HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

Unknown
NCT02893124Phase 4

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Unknown
NCT01343186Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8